Keywords: Endo Pharma, BioDelivery Sciences, Buprenorphine, Narcotic analgesic, Transmucosal form

Endo Pharma in $180 million deal with BioDelivery Sciences

Article | 08 January 2012

US drugmaker Endo Pharmaceuticals (Nasdaq: ENDP) has signed a worldwide license and development agreement with USA-based BioDelivery Sciences International (Nasdaq: ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Endo Pharmaceuticals

BioDelivery Sciences

Go to company listing

Related Drugs

Buprenorphine

Go to drug listing